Consequently, immune-checkpoint inhibitors (ICIs) targeting PD-1/PD-L1, and CTLA-4 were the first to be developed, demonstrating unprecedented benefits in selected patients and reshaping the therapeutic landscape for numerous cancers (13). The gene discussed is CTLA4; the disease is cancer.